Breaking News Instant updates and real-time market news.

SLS

Sellas Life Sciences

$0.52

-0.0049 (-0.94%)

08:44
06/03/19
06/03
08:44
06/03/19
08:44

Sellas Life Sciences announces results from trastuzumab +/- NPS trial at ASCO

Sellas Life Sciences announced results from a preplanned analysis of immunologic responses in the cohort of patients with triple negative breast cancer, or TNBC, from the prospective, randomized, single-blinded, controlled Phase 2b independent investigator-sponsored clinical trial of nelipepimut-S, or NPS, +/- trastuzumab targeting HER2 low-expressing breast cancer patients. This analysis was presented at the American Society of Clinical Oncology, or ASCO. The Phase 2b study enrolled patients with HER2-low expressing breast cancer who remained clinically disease-free after completion of frontline standard of care therapy. Patients were selected to harbor node-positive disease and/or TNBC, as well as expressing human leukocyte antigen, or HLA, types indicated for NPS administration. Patients were randomized to placebo with granulocyte-macrophage colony-stimulating factor or NPS with GM-CSF, while they all received trastuzumab every 3 weeks for one year. The company previously reported results of the final analysis of efficacy and safety outcomes in the cohort of patients whose tumors did not express hormone receptors. DFS of patients treated with NPS plus trastuzumab was 92.6% compared to 70.2% for those treated with trastuzumab alone and represented a clinically meaningful and a statistically significant improvement with the combination therapy. This was associated with a statistically significant reduction by 71.9% in the frequency of clinically detected recurrences in favor of the combination in the TNBC cohort. Ninety-one of the 97 TNBC patients in this clinical study were analyzed for immune responses, or IR, at five timepoints, 51 of whom received the combination therapy. IR were evaluated ex vivo by clonal expansion of antigen NPS-specific cytotoxic T-lymphocytes, or CTL, by dextramer-staining/flow cytometry at predefined time points over three years. In vivo IR were assessed by cutaneous delayed type hypersensitivity, or DTH, reactions periodically, by measuring the diameter of skin induration post intradermal NPS treatment. NPS plus trastuzumab-treated TNBC patients exhibited increases in CTL frequencies compared with baseline. The mean CTL frequencies in these patients increased at baseline at a 2.86-fold difference that was clinically indicative, as compared with patients receiving trastuzumab only. Three patients in the combination arm recurred as compared with 12 in the trastuzumab-alone arm. TNBC patients treated with NPS plus trastuzumab whose disease recurred did not mount an IR by ex vivo assessment or by in vivo DTH, while non-recurrent patients mounted both vigorous NPS-specific clonal CTL expansion and enhanced in vivo DTH.

SLS Sellas Life Sciences
$0.52

-0.0049 (-0.94%)

11/01/18
11/01/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Tesla (TSLA) initiated with a Neutral at Roth Capital. 2. T-Mobile (TMUS) initiated with a Buy at Guggenheim. 3. Kosmos (KOS) initiated with a Buy at Berenberg. 4. Sellas Life Sciences (SLS) initiated with an Outperform at Oppenheimer. 5. OFS Credit (OCCI) initiated with a Buy at Ladenburg. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
03/22/19
MAXM
03/22/19
DOWNGRADE
MAXM
Hold
Sellas Life Sciences downgraded to Hold from Buy at Maxim
03/25/19
03/25/19
DOWNGRADE

Hold
Sellas Life Sciences downgraded to Hold from Buy at Maxim
As previously reported, Maxim analyst Jason McCarthy downgraded Sellas Life Sciences to Hold, saying the company's "tight" cash balance will likely require it to raise capital to support the planned Phase 3 study of galinpepimut-S, or GPS. The analyst maintains however that Sellas Life Sciences fundamentals remain intact, and his positive views around GPS and Nelipepimut-S, or NPS, remain unchanged.
04/08/19
04/08/19
INITIATION
Target $4.5

Buy
Sellas Life Sciences initiated with a Buy at Alliance Global Partners
Alliance Global Partners analyst James Molloy initiated Sellas Life Sciences with a Buy and $4.50 price target.

TODAY'S FREE FLY STORIES

I

Intelsat

$24.59

0.26 (1.07%)

11:05
10/14/19
10/14
11:05
10/14/19
11:05
Options
Intelsat call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DE

Deere

$169.81

-1.16 (-0.68%)

11:03
10/14/19
10/14
11:03
10/14/19
11:03
Hot Stocks
Deere to acquire Unimil, terms not disclosed »

Deere & Company has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

SDC

SmileDirectClub

$10.48

-0.62 (-5.59%)

11:01
10/14/19
10/14
11:01
10/14/19
11:01
Hot Stocks
Breaking Hot Stocks news story on SmileDirectClub »

SmileDirectClub says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

SDC

SmileDirectClub

$10.44

-0.66 (-5.95%)

11:00
10/14/19
10/14
11:00
10/14/19
11:00
Hot Stocks
SmileDirectClub says CA assembly bill 1519 creates 'unnecessary hurdles' »

SmileDirectClub issued a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

TPR

Tapestry

$24.69

-1.28 (-4.93%)

10:55
10/14/19
10/14
10:55
10/14/19
10:55
Options
Tapestry put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 07

    Nov

10:55
10/14/19
10/14
10:55
10/14/19
10:55
Conference/Events
Evercore REITs analyst to hold a luncheon »

REITs Analyst Sakwa holds…

PUBGY

Publicis

$0.00

(0.00%)

, DIS

Disney

$129.71

-0.37 (-0.28%)

10:54
10/14/19
10/14
10:54
10/14/19
10:54
Periodicals
Disney splitting $3B media business with Publicis, Omnicom, Campaign reports »

Disney (DIS) is set to…

PUBGY

Publicis

$0.00

(0.00%)

DIS

Disney

$129.71

-0.37 (-0.28%)

OMC

Omnicom

$74.82

0.17 (0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 24

    Oct

  • 24

    Oct

  • 07

    Nov

ALXN

Alexion

$99.63

0.37 (0.37%)

10:45
10/14/19
10/14
10:45
10/14/19
10:45
Options
Alexion call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 23

    Oct

WDC

Western Digital

$59.26

0.9 (1.54%)

, AAPL

Apple

$237.68

1.47 (0.62%)

10:39
10/14/19
10/14
10:39
10/14/19
10:39
On The Fly
Western Digital rises as analyst says buy on rising flash prices »

Shares of Western Digital…

WDC

Western Digital

$59.26

0.9 (1.54%)

AAPL

Apple

$237.68

1.47 (0.62%)

STX

Seagate

$53.60

-0.2 (-0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 01

    Nov

  • 04

    Nov

  • 14

    Nov

  • 19

    Nov

  • 20

    Nov

HUM

Humana

$264.13

-2.2 (-0.83%)

10:34
10/14/19
10/14
10:34
10/14/19
10:34
Hot Stocks
Humana among five MA plans selected for Florida Medicare retirees »

Humana (HUM), which…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

  • 13

    Nov

EHTH

eHealth

$54.37

-1.61 (-2.88%)

10:29
10/14/19
10/14
10:29
10/14/19
10:29
Recommendations
eHealth analyst commentary  »

eHealth churn concerns…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

BHC

Bausch Health

$20.50

-0.12 (-0.58%)

10:25
10/14/19
10/14
10:25
10/14/19
10:25
Options
Bausch Health call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Nov

GNUS

Genius Brands

$0.83

0.06 (7.79%)

10:25
10/14/19
10/14
10:25
10/14/19
10:25
Conference/Events
Genius Brands to host business news update conference call »

Conference call to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Oct

10:25
10/14/19
10/14
10:25
10/14/19
10:25
Conference/Events
UBS technology analyst to hold an analyst/industry conference call »

Technology Analyst…

SDC

SmileDirectClub

$10.56

-0.54 (-4.86%)

10:20
10/14/19
10/14
10:20
10/14/19
10:20
Recommendations
SmileDirectClub analyst commentary  »

SmileDirectClub may or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

10:17
10/14/19
10/14
10:17
10/14/19
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

10:16
10/14/19
10/14
10:16
10/14/19
10:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WLL

Whiting Petroleum

$6.94

-0.5 (-6.72%)

10:15
10/14/19
10/14
10:15
10/14/19
10:15
Options
Whiting Petroleum put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PING

Ping Identity

$16.72

0.25 (1.52%)

, NVST

Envista

$27.55

-0.32 (-1.15%)

10:09
10/14/19
10/14
10:09
10/14/19
10:09
Initiation
Fly Intel: Top five analyst initiations »

Catch up on today's…

PING

Ping Identity

$16.72

0.25 (1.52%)

NVST

Envista

$27.55

-0.32 (-1.15%)

DDOG

Datadog

$36.25

0.58 (1.63%)

BYND

Beyond Meat

$125.99

-5.41 (-4.12%)

BE

Bloom Energy

$3.11

-0.055 (-1.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 19

    Nov

  • 04

    Dec

FAST

Fastenal

$35.95

-0.41 (-1.13%)

, AMCX

AMC Networks

$46.77

-1.65 (-3.41%)

10:09
10/14/19
10/14
10:09
10/14/19
10:09
Downgrade
Fly Intel: Top five analyst downgrades »

Catch up on today's…

FAST

Fastenal

$35.95

-0.41 (-1.13%)

AMCX

AMC Networks

$46.77

-1.65 (-3.41%)

DAL

Delta Air Lines

$52.44

-0.5 (-0.94%)

TOL

Toll Brothers

$39.32

-0.17 (-0.43%)

CGC

Canopy Growth

$18.66

-0.76 (-3.91%)

HEXO

Hexo

$2.38

-0.155 (-6.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

  • 31

    Oct

  • 12

    Nov

  • 12

    Nov

NKE

Nike

$94.70

0.8 (0.85%)

, WDC

Western Digital

$59.86

1.5 (2.57%)

10:09
10/14/19
10/14
10:09
10/14/19
10:09
Upgrade
Fly Intel: Top five analyst upgrades »

Catch up on today's…

NKE

Nike

$94.70

0.8 (0.85%)

WDC

Western Digital

$59.86

1.5 (2.57%)

VAR

Varian Medical

$112.50

1.72 (1.55%)

XLNX

Xilinx

$96.70

0.52 (0.54%)

HPE

HP Enterprise

$14.77

0.42 (2.93%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Oct

  • 22

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 14

    Nov

  • 19

    Nov

  • 20

    Nov

LK

Luckin Coffee

$18.99

-0.025 (-0.13%)

10:05
10/14/19
10/14
10:05
10/14/19
10:05
Options
Luckin Coffee call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVST

Envista

$27.55

-0.32 (-1.15%)

10:02
10/14/19
10/14
10:02
10/14/19
10:02
Initiation
Envista initiated  »

Envista initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EHTH

eHealth

$53.10

-2.88 (-5.14%)

10:01
10/14/19
10/14
10:01
10/14/19
10:01
Periodicals
eHealth lower following cautious Off Wall Street mention »

Shares of eHealth are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

SAFM

Sanderson Farms

$148.68

-1.2 (-0.80%)

10:00
10/14/19
10/14
10:00
10/14/19
10:00
Conference/Events
Sanderson Farms to host investor day »

Investor day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 13

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.